Ann: Appendix 4D Half Yearly Report and Accounts , page-5

re: Ann: Appendix 4D Half Yearly Report and A... With a current cap of $12 M it’s hard to see anyone willing to pay $50-70M for GBI.
Previous sales of HPV testing assets are now irrelevant as a guide because they occurred well before the wheels fell off the world economy.

In 2006 Qiagen paid $22 M to acquire the rest of Genaco to develop multiplex PCR for its HPV assays, which could be a bit of an indicator of GBI value, even though in retrospect 2006 was boom times for the sharemarket.

A positive trial result will spike the GBI share price (I hope) and the similarity to the Qiagen HPV systems should generate buyer interest.